Abstract: One aspect of the present invention relates to a recovery method of 226Ra, and the recovery method of 226Ra includes a step (A1) of immersing a solid-state 226Ra containing substance and a carrier having a function of adsorbing 226Ra ions in a processing solution, and then irradiating the processing solution with ultrasonic waves.

Abstract: The present invention relates to a method for producing a radioactive zirconium-labeled complex that can realize a high labeling index in a reaction between a radioactive zirconium ion and a ligand compound. The production method of the present invention includes a step of reacting a radioactive zirconium ion with a ligand compound in a reaction solution containing water to coordinate the radioactive zirconium ion. This step is performed in a state where the pH of the reaction solution is in an acidic region. The reaction solution does not contain an organic solvent but contains a water-soluble organic compound having one or two sulfo groups or carboxy groups in its structure, separately from the ligand compound.

Abstract: A conjugate of an anti-HER2 antibody site-specifically modified with a peptide and a chelating agent. The chelating agent is chelated with a metal radionuclide, the peptide and the chelating agent are linked by a linker (L), and the linker (L) does not contain a thiourea bond. A radiopharmaceutical including the conjugate as an active ingredient.

Abstract: A method for producing a radioactive zirconium complex of the present invention includes a step of reacting a radioactive zirconium ion, a ligand compound containing DOTA or a DOTA derivative, and an additive such as hydroxybenzoic acid and a derivative thereof with one another in a reaction solution to form a radioactive zirconium complex. As the reaction solution, a reaction solution is used in which the amount of radioactivity of the radioactive zirconium ion is 60 MBq or more at the start of the reaction and the amount of radioactivity of the radioactive zirconium ion is 5 MBq or more per 1 nmol of the ligand compound at the start of the reaction.

Abstract: A method for producing an 225Ac solution includes a step (I) of irradiating a 226Ra target with particles to generate two or more actinium radioisotopes (Ac) including at least 225Ac, a step (II) of dissolving the 226Ra target after the aforementioned step to obtain a solution (1), a step (III) of separating 226Ra and Ac contained in the solution (1) to obtain a solution (2), a step (IV) of allowing Ac contained in the solution (2) other than 225Ac to decay to obtain a solution (3), and a step (V) of separating Ra and Ac contained in the solution (3) to obtain a solution (4). The solution (4) is used to produce a medicine that contains, as an active ingredient, a conjugate between a chelating agent that has formed a complex with 225Ac, and a targeting agent.

Abstract: A method for producing 225Ac solution includes steps (I) to (III): a step (I) of passing a solution containing 226Ra and 225Ac through a solid-phase extraction agent (a) that contains a compound represented by formula (A) so as to cause the solid-phase extraction agent (a) to retain 225Ac; a step (II) of passing a liquid containing an eluate, which is obtained by eluting the retained 225Ac from the solid-phase extraction agent (a), through a solid-phase extraction agent (b) that contains a compound represented by formula (B) so as to cause the solid-phase extraction agent (b) to retain 225Ac; and a step (III) of eluting the retained 225Ac from the solid-phase extraction agent (b) to obtain an 225Ac solution.

Abstract: A radionuclide analysis apparatus includes: a radiation data detection unit that detects energy of alpha-ray emitted from a radionuclide in a sample and another energy emitted from another radionuclide different from the energy of the alpha-ray; a nuclide identification unit that identifies the radionuclide that has emitted the radiation by comparing a measurement spectrum Sa that is an energy spectrum based on the energy of the alpha-ray or another energy detected by the radiation data detection unit with a standard spectrum Ssa; and a distribution acquisition unit that obtains a distribution of a specific nuclide identified by the nuclide identification unit in the sample.

Abstract: A method for producing an 225Ac solution includes a step (I) of irradiating a 226Ra target with particles to generate two or more actinium radioisotopes (Ac) including at least 225Ac, a step (II) of dissolving the 226Ra target after the aforementioned step to obtain a solution (1), a step (III) of separating 226Ra and Ac contained in the solution (1) to obtain a solution (2), a step (IV) of allowing Ac contained in the solution (2) other than 225Ac to decay to obtain a solution (3), and a step (V) of separating Ra and Ac contained in the solution (3) to obtain a solution (4). The solution (4) is used to produce a medicine that contains, as an active ingredient, a conjugate between a chelating agent that has formed a complex with 225Ac, and a targeting agent.

Abstract: The production method of a radioactive metal-labeled antibody of the present invention includes a step of conducting a click reaction of a radioactive metal complex and an antibody site-specifically modified with a peptide to produce a radioactive metal-labeled antibody. The click reaction is performed between a first atomic group of the radioactive metal complex and a second atomic group directly or indirectly linked to the peptide. The second atomic group is an atomic group containing an azide group, or an atomic group containing trans-cyclooctene.

Abstract: Described is a labeling technique which can facilitate the metabolism in the liver after administration to patients without the reduction in the antibody function, thereby reducing accumulation of radionuclides in an organ such as the liver, and a modified antibody containing an IgG antibody and an IgG-binding peptide bound to the IgG antibody. The IgG-binding peptide has an amino acid sequence consisting of 13 to 17 amino acid residues, such as GPDCAYH(Xaa1)GELVWCTFH (SEQ ID NO: 2) wherein Xaa1 represents a lysine residue, a cysteine residue, an aspartic acid residue, a glutamic acid residue, 2-aminosuberic acid, or diaminopropionic acid, and a compound represented by the following formula (II-1) is linked at a position of the lysine residue via a modification linker to the N terminus of the IgG-binding peptide.

Abstract: In a compound of the present invention, in a macroscopic view of a chemical structure thereof, a chelating moiety is located at the center of the structure, an atomic group containing an albumin binding moiety binds to one side of the chelating moiety, and an atomic group containing a target molecule binding moiety binds to the other side of the chelating moiety. The chelating moiety is also preferably DOTA or a derivative thereof. The target molecule binding moiety preferably has a structure to bind to a target molecule expressed in a cancer tissue. The present invention also provides a radioactive labeled compound in which the compound is coordinated to a radioactive metal ion.

Abstract: The RI-labeled anti-MUC5AC humanized antibody of the present invention is a conjugate of a chelating agent chelated with a radionuclide and an antibody (the radionuclide is a metal nuclide that emits ? particle or positron, and the antibody is a humanized antibody specifically binding to MUC5AC), and is superior in specificity for MUC5AC and accumulation in tumor. Therefore, it is extremely useful for the treatment and/or diagnosis of diseases in which MUC5AC is overexpressed, particularly cancer.

Abstract: A method for producing 225A including: a method (X) for purifying a 226Ra-containing solution, including an adsorption step of allowing a 226Ra ion to adsorb onto a carrier having a function of selectively adsorbing a divalent cation by bringing a 226Ra-containing solution into contact with the carrier under an alkaline condition, and an elution step of eluting the 226Ra ion from the carrier under an acidic condition; a method for producing a 226Ra target, including an electrodeposition liquid preparation step of preparing an electrodeposition liquid by using a purified 226Ra-containing solution obtained by the method (X), and an electrodeposition step of electrodepositing a 226Ra-containing substance on a substrate by using the electrodeposition liquid; and a step of irradiating a 226Ra target produced by the method for producing a 226Ra target with at least one selected from a charged particle, a photon, and a neutron by using an accelerator.

Abstract: A method for producing an 225Ac solution includes a step (I) of irradiating a 226Ra target with particles to generate two or more actinium radioisotopes (Ac) including at least 225Ac, a step (II) of dissolving the 226Ra target after the aforementioned step to obtain a solution (1), a step (III) of separating 226Ra and Ac contained in the solution (1) to obtain a solution (2), a step (IV) of allowing Ac contained in the solution (2) other than 225Ac to decay to obtain a solution (3), and a step (V) of separating Ra and Ac contained in the solution (3) to obtain a solution (4). The solution (4) is used to produce a medicine that contains, as an active ingredient, a conjugate between a chelating agent that has formed a complex with 225Ac, and a targeting agent.

Abstract: An object of the present invention is to provide a method for purifying efficiently and easily a 226Ra-containing solution obtained when 225Ac is produced from a 226Ra target, a method for producing a 226Ra target by using the purified 226Ra-containing solution obtained by the above purification method, and a method for producing 225Ac including these above methods. The method for purifying a 226Ra-containing solution according to the present invention is characterized by including an adsorption step (R1) of allowing 226Ra ions to adsorb onto a carrier having a function of selectively adsorbing divalent cations by bringing a 226Ra-containing solution (a) into contact with the carrier under an alkaline condition; and an elution step (R2) of eluting the 226Ra ions from the carrier under an acidic condition.

Abstract: One embodiment of the present invention relates to a production method of a 226Ra target, a production method of 225Ac, or an electrodeposition solution for producing a 226Ra target, and the production method of a 226Ra target includes an electrodeposition step of electrodepositing a 226Ra-containing substance on a substrate by using an electrodeposition solution that contains 226Ra ions and a pH buffer.

Abstract: One embodiment of the present invention relates to a production method of 225Ac includes; a production step of a 226Ra target including an electrodeposition step of electrodepositing a 226Ra-containing substance on a substrate by using an electrodeposition solution that contains 226Ra ions and a pH buffer, and an irradiating step of irradiating the 226Ra target with at least one selected from charged particles, photons, and neutrons.

Abstract: A method for producing 225A including: a method (X) for purifying a 226Ra-containing solution, including an adsorption step of allowing a 226Ra ion to adsorb onto a carrier having a function of selectively adsorbing a divalent cation by bringing a 226Ra-containing solution into contact with the carrier under an alkaline condition, and an elution step of eluting the 226Ra ion from the carrier under an acidic condition; a method for producing a 226Ra target, including an electrodeposition liquid preparation step of preparing an electrodeposition liquid by using a purified 226Ra-containing solution obtained by the method (X), and an electrodeposition step of electrodepositing a 226Ra-containing substance on a substrate by using the electrodeposition liquid; and a step of irradiating a 226Ra target produced by the method for producing a 226Ra target with at least one selected from a charged particle, a photon, and a neutron by using an accelerator.

Abstract: A method for producing a radioactive metal complex includes a step of allowing a radioactive metal to react with DOTA or a derivative thereof as a ligand in a reaction liquid to form a radioactive metal complex. The reaction liquid contains water, a buffer, and a water-soluble organic solvent. The radioactive metal is 89Zr or 225Ac. The ligand may have, in the structure thereof, a group to which a peptide is linked. The content of the water-soluble organic solvent in the reaction liquid is preferably 2% by volume or more and 50% by volume or less. The radioactive metal is preferably allowed to react with the ligand in the reaction liquid at 30° C. or higher and 80° C. or lower.

Abstract: The RI-labeled anti-MUC5AC humanized antibody of the present invention is a conjugate of a chelating agent chelated with a radionuclide and an antibody (the radionuclide is a metal nuclide that emits ? particle or positron, and the antibody is a humanized antibody specifically binding to MUC5AC), and is superior in specificity for MUC5AC and accumulation in tumor. Therefore, it is extremely useful for the treatment and/or diagnosis of diseases in which MUC5AC is overexpressed, particularly cancer.